Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Developers’ Perspective on Streamlining the Biosimilar Development Process

January 2nd 2024

By Deana Ferreri, PhD

Article

The regulatory structure of biosimilar development can be safely streamlined and made more efficient and less costly, wrote authors from Sandoz, Fresenius Kabi, Boehringer Ingelheim, and Samsung Bioepis in an opinion article published in BioDrugs.

The Top 5 Most-Read Rheumatology Stories of 2023

January 1st 2024

By Skylar Jeremias

Article

The top 5 most-read rheumatology stories of 2023 included the changing market dynamics in the adalimumab space, including new launches and interchangeability labels, as well as the addition of Stelara and Enbrel to the list of originators up for Medicare price negotiation.

A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond

December 31st 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.

The Top 5 Most-Read Regulatory Stories of 2023

December 30th 2023

By Skylar Jeremias

Article

The top 5 most-read regulatory stories of 2023 covered the FDA approvals for the first ustekinumab biosimilar and the first subcutaneous infliximab product, as well as other regulatory updates.

The Top 5 Biosimilar Articles of 2023

December 29th 2023

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for 2023.

The Top 5 Most-Read Conference Stories of 2023

December 28th 2023

By Skylar Jeremias

Article

The top 5 most-read conference stories of 2023 recapped some of big biosimilar takeaways from this year’s conferences, including insight into how geopolitics will impact the industry, efforts from government agencies, and strategies to increase biosimilar uptake.

The Top 5 Most-Read Oncology Stories of 2023

December 27th 2023

By Skylar Jeremias

Article

The top 5 most-read oncology stories of 2023 include the US market launch of Fylnetra, the sixth pegfilgrastim biosimilar on the market, the FDA approval for an autoinjector pegfilgrastim biosimilar, and more.

The Top 5 Most-Listened Podcasts of 2023

December 26th 2023

By Skylar Jeremias

Article

The top 5 most-listened podcast episodes of 2023 covered a range of topics including the US market introduction of adalimumab biosimilars, current market trends, the role of providers in boosting adoption rates, and more.

The Top 5 Most-Read Gastroenterology Stories of 2023

December 25th 2023

By Skylar Jeremias

Article

The top 5 most-read gastroenterology stories of 2023 examined clinical data for adalimumab biosimilars, some Canadian regulatory news, and inflation rate predictions from Vizient.

Cencora's Brian Biehn and Corey Ford Recommend Adaptations for Biosimilar Regulatory Frameworks

December 24th 2023

By Skylar Jeremias

Video

Brian Biehn and Corey Ford from Cencora suggest improvements to current regulatory frameworks to better promote biosimilars for US patients and ensure market sustainability.